Boston Scientific earnings loom with cyberattack impact on deck

Boston Scientific (BSX) reports Q3 earnings on Wednesday, with analysts expecting $0.75 EPS on $5.12B revenue, down from Q2. An August cyberattack disrupted operations, leading to lowered guidance and a 10% cut in revenue projections. Despite near-term challenges, 24 of 30 analysts rate the stock a Buy with a $57.82 price target. Competitive pressure on its Watchman device adds to uncertainties.

Original reporting
Published Oct 27, 2026, 3:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 3:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$BSX
Bearish
high confidence
Mentioned
$BSX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BSXBearishMed
01

Why it matters

The guidance downgrade reflects a ~10% revenue reduction across divisions, increasing short‑term risk for the stock.

02

Market read

First report of revised Q3 guidance for a mid‑cap healthcare stock, introducing new downside risk.

03

What to watch

Potential upside from competitive pressure on Abbott's Watchman device may be muted by the cyber incident.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Boston Scientific disclosed a major August cyberattack that disrupted manufacturing and order processing, prompting a revision of its Q3 outlook.

Company-level read

Ticker impact

$BSXBearishHigh confidence
Context

Boston Scientific (BSX) forecasts Q3 EPS of $0.75 on $5.12B revenue after a cyberattack forced it to cut guidance.

Expected impact

likely pressure as investors price in lower revenue and earnings

Evidence & confidence

Guidance is materially below prior expectations and the cyber incident adds uncertainty.

Market effects

Medical device sector may see broader risk reassessment for cyber‑exposure.

U.S. healthcare stocks could face modest pullback ahead of earnings season.

Limited to investors tracking U.S. med‑tech equities.

Counterpoint

If the cyberattack impact is short‑lived, the stock could rebound on a beat in Q4 guidance.

Key entities

  • Boston Scientific Corp.

    Medical device maker reporting Q3 earnings guidance.

  • Abbott Laboratories

    Competitor mentioned for its Watchman device.

Related articles

$BSXMed

BSX's Weak Solvency and Cash Conversion Raise Financing Risk

Boston Scientific (BSX) reported $609M in cash, $11.95B in debt, and Q3 free cash flow of $867M. Adjusted gross margin fell 300bps YoY to 68% due to a cybersecurity incident. BSX lowered its full-year free cash flow outlook to $3.6B. The company faces margin pressure, pricing pressure in China, and acquisition-related obligations. BSX shares have declined 56% YoY, trading at a 12-month forward P/S of 3.00X. Analysts have reduced BSX's 2026 earnings estimate by 2.2% over the past 30 days.

$PHGMed

New Study Shows How Hybrid Imaging Can Guide Coronary Treatment Decisions

Conavi Medical (TSXV: CNVI, OTCQB: CNVIF) received FDA 510(k) clearance for its hybrid imaging system, combining IVUS and OCT. The company reported first U.S. commercial placement, early clinical benefits, and extended credit facilities. Peer-reviewed research supports hybrid imaging for coronary treatment decisions. Conavi aims to expand physician adoption and hospital placements.